Clinical Trial Update: Efficacy and Safety of CD19CD20-CAR.p40-T in B-cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial is evaluating the efficacy and safety of CD19CD20-CAR.p40-T in relapsed/refractory B-cell lymphoma and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma

Drugs mentioned

• CD19CD20-CAR.p40-T

Snippet

Sponsor: Shenzhen University General Hospital | Conditions: Relapsed/Refractory B-cell Lymphoma | Phase 1, Phase 2 | Status: RECRUITING